Antisense Drug Technology: Principles: Strategies, and Applications
Purchasing Options
Summary
This state-of-the-art reference provides comprehensive coverage of the development of antisense oligonucleotides to inhibit cancer cells as well as those involved in infectious, inflammatory, and immune-mediated diseases-highlighting new tools and technologies in medicinal chemistry, RNA biochemistry, and molecular and cellular biology to produce new therapeutic compounds.
Presents previously unpublished data on the use of antisense technology to dissect pharmacological processes and confirm the roles of various genes!
Showcasing the benefits of antisense drug use, including reduced toxicity and earlier disease detection, Antisense Drug Technology discusses
With contributions by over 60 seasoned experts in the field and containing more than 3000 helpful references, tables, drawings, and photographs, Antisense Drug Technology is an illuminating source for organic, medicinal, and pharmaceutical chemists; biochemists; geneticists; hematologists; oncologists; molecular and cell biologists; virologists; immunologists; and medical school and graduate students in these disciplines.
Table of Contents
Basic Principles of Antisense Technology
Stanley T. Crooke
Medicinal Chemistry of Antisense Oligonucleotides
P. Dan Cook
Analytical Methods for Antisense Drugs
Janet M. Leeds and Lendell L. Cummins
A Role for Antisense Technology in the Discovery of Highly Specific and Versatile Signal Transduction Inhibitors
Brett P. Monia, Erich Koller, and William A. Gaarde
Methods of Selecting Sites in RNA for Antisense Targeting
Susan M. Freier
Properties of Phosphorothioate Oligonucleotides
Pharmacokinetic Properties in Animals
Richard S. Geary, Rosie Z. Yu, Janet M. Leeds, Michael V. Templin, Tanya A. Watanabe, Scott P. Henry, and Arthur A. Levin
Suborgan Pharmacokinetics
Rosanne M. Crooke and Mark J. Graham
Pharmacokinetic Properties in Humans
Rosie Z. Yu, Steven L. Schoenfeld, Richard S. Geary, Tanya A. Watanabe, and Arthur A. Levin
Toxicity of Antisense Oligonucleotides
Arthur A. Levin, Scott P. Henry, David Monteith, and Michael V. Templin
Clinical Safety of Phosphorothioate Oligodeoxynucleotides
F. Andrew Dorr, Josephine M. Glover, and T. Jesse Kwoh
General Pharmacology of Phosphorothioate Oligodeoxynucleotides
C. Frank Bennett
Properties of Advanced Novel Clinical Classes of Oligonucleotides
Pharmacology of 2´-0-(2-Methoxy)ethyl Modified Antisense Oligonucleotides
Nicholas M. Dean, Madeline Butler, Brett P. Monia, and Muthiah Manoharan
Locked Nucleic Acid
Jesper Wengel
Antisense Properties of Peptide Nucleic Acid (PNA)
Uffe Koppelhus and Peter J. Nielsen
Phosphorodiamidate Morpholino Oligomers
Patrick Iversen
Oligonucleotide Conjugates in Antisense Technology
Muthiah Manoharan
Immune Stimulation by Oligonucleotides
Arthur M. Krieg
Pre-mRNA Splicing as a Target for Antisense Oligonucleotides
Ryszard Kole and Danielle Mercatante
Application of Antisense Oligonucleotides to the Study of CNS Protein Function
Siew Peng Ho
Antisense Approach to Isoform-Specific Blockade of Acetylcholinesterase
Hermona E. Soreq and Shlomo Seidman
Serine/Threonine Protein Phosphates
Richard E. Honkanen
Pharmacological Activities of Antisense Drugs: Inflammatory Diseases
James G. Karras, Kathleen J. Myers, and Brenda F. Baker
Respirable Antisense Oligonucleotides (RASONs)
Jonathan W. Nyce
Combined Antisense Therapy and Chemotherapy in Animal Models
Dan Mercola
Antisense Oligodesoxynucleotide Strategies in Renal and Cardiovascular Disease
Hermann Haller, Christian Maasch, Duska Dragun, Maren Wellner, and Friedrich C. Luft
The Development of Antisense Oligonucleotides as Antivirals
Lisa R. Grillone
Clinical Activities in Patients with Solid Tumors or Lymphoma
Jon T. Holmlund
Nucleic Acid Therapeutics for the Treatment of Human Leukemia
Alan M. Gewirtz
ISIS 2302, an Antisense Inhibitor of Intercellular Adhesion Molecule 1 (ICAM-1)
William R. Shanahan, Jr.
New Routes and Novel Formulations for Delivery of Antisense Oligonucleotides
Gregory E. Hardee, Susan P. Weinbach, and Lloyd G. Tillman
DNA-Binding Molecules
Roland W. Bürli and Heinz E. Moser
Targeted Genome Modification via Triple Helix Formation
Margaret A. Macris and Peter M. Glazer
Intracellular Ribozyme Applications
John J. Rossi